HUE033695T2 - K-RAS mutációk és anti-EGFR antitest-terápia - Google Patents

K-RAS mutációk és anti-EGFR antitest-terápia Download PDF

Info

Publication number
HUE033695T2
HUE033695T2 HUE12154109A HUE12154109A HUE033695T2 HU E033695 T2 HUE033695 T2 HU E033695T2 HU E12154109 A HUE12154109 A HU E12154109A HU E12154109 A HUE12154109 A HU E12154109A HU E033695 T2 HUE033695 T2 HU E033695T2
Authority
HU
Hungary
Prior art keywords
ras
lys
asp
polypeptide
val
Prior art date
Application number
HUE12154109A
Other languages
English (en)
Inventor
Daniel Freeman
Todd Juan
Robert Radinsky
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033695(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HUE033695T2 publication Critical patent/HUE033695T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (4)

  1. K-RAS MUTÁCIÓK ÉS AN'H-E€KR ANTITEST-TERÁPIA S«#aifgihfi IglHypöötfiik î. kijárás annak jóslására, hogy colorecmhs rákban szenvedő ;\κ kus pauuutnmnabhal <,égz:e»t kezeié;;:«i szemben érzéketlen lesx-e, atneîy eljárás iartalmazza a páesens tumorjában K-mk-ban T20M és GlùV mutée s-nk jelenlétének. vagy hiányának meghatározását ahoi amunkioh jdeniéte azt jelzi, hogy a páciens pantmrsnmabbaí végzett kezelésre érzékében lesz.
  2. 2. Ah í . igénypont szerinti eljárás, ahol K-ras-ban a T20M ès a G12V mutációk jelenléte vagy hiarua meghatározásának lépese iartaiinazza mt-tAns; K-ras-polipepud kimutatását a páciensből szárma«1» tumorirnHta-bas, tnutám; K-ras-pobpep;isihez kötötló, specifikus kötövegyiUet alkalmazásával.
  3. 3. Az 3. igény-pont szerinti eljárás, ahol K-ras-ba» a 'Ï20M és a C12V mutációk jelenléte, vagy hiánya meghatározásának lépése tartalmazza mtkicinssv kinyerését a páctenebSÍ$#.mazó. tm&amp;t'é&amp;iiáböi. a mxkkirtsa1v amplifi-kálását és az ampUfrkáit tníkieiösavkssekwnálását,
  4. 4. Eljárás annak jóslására, hogy colorectal»* iákból származó tumor panitumutnabbal végzett kezeléssel; szemben érzéketlen lesz-e, amely eljárás tartalmazza a tumor tóin tájában K-ras-ban Γ20Μ és G12V mutáció; jelenlétének vagy hiányának meghatározását, ahol a nunádó jelenléte ezt jelzi, hogy a tumor paniiBnmnuxbbat; végzet- kezelésre érzék ellen lesz, 4. tgérsypí-nt s?e«ntt eljárás, ahol &amp; tumor mintájában K-rás-bsn a T211M és a G12V MutáehÉ jelem· léte vagy hiánya nteghaíározásáftak lépése taríahmtsssa mutáns K-ras-poH|^^kteuM^'-a ftämöf .mttőíájábán» máiáss specifikus kétóvegyüiet aiksitnazásávitL ő. A :4 tgénypems szerinti eljárás, almi K-ras-bat? a T20M es a GI2V mytéb!áfá|igfe8Mt#Á'^-'iííáaya ampliiikálását a tömör mintájából, és az itv^iiliMit «ttklélhsav szék ve-ná Sását.
HUE12154109A 2007-03-13 2008-03-11 K-RAS mutációk és anti-EGFR antitest-terápia HUE033695T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90694307P 2007-03-13 2007-03-13

Publications (1)

Publication Number Publication Date
HUE033695T2 true HUE033695T2 (hu) 2017-12-28

Family

ID=39689242

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12154109A HUE033695T2 (hu) 2007-03-13 2008-03-11 K-RAS mutációk és anti-EGFR antitest-terápia

Country Status (21)

Country Link
US (3) US20080293055A1 (hu)
EP (2) EP2121989B2 (hu)
JP (1) JP2010521153A (hu)
AR (1) AR065687A1 (hu)
AU (1) AU2008226803A1 (hu)
CA (1) CA2680326A1 (hu)
CL (1) CL2008000717A1 (hu)
CY (2) CY1115333T1 (hu)
DK (2) DK2121989T4 (hu)
ES (2) ES2635051T3 (hu)
HR (2) HRP20140360T4 (hu)
HU (1) HUE033695T2 (hu)
LT (1) LT2465950T (hu)
MX (1) MX2009009787A (hu)
PE (1) PE20081880A1 (hu)
PL (2) PL2121989T5 (hu)
PT (2) PT2121989E (hu)
RS (2) RS56422B1 (hu)
SI (2) SI2121989T2 (hu)
TW (1) TW200902553A (hu)
WO (1) WO2008112269A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
WO2008112274A2 (en) * 2007-03-13 2008-09-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
US8502015B1 (en) 2009-07-06 2013-08-06 Transgenex Nanobiotech, Inc. Method of inducing cancer
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
NZ602920A (en) * 2010-04-12 2014-07-25 Response Genetics Inc Kras primers and probes
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
EP2776043B1 (en) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
SG11201501662TA (en) 2012-09-04 2015-05-28 Guardant Health Inc Systems and methods to detect rare mutations and copy number variation
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en) 2012-09-04 2024-02-27 Guardent Health, Inc. Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en) 2012-09-04 2020-12-29 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
SG10201707548RA (en) * 2013-03-19 2017-10-30 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
EP3524694B1 (en) 2013-12-28 2020-07-15 Guardant Health, Inc. Methods and systems for detecting genetic variants
EP3805404A1 (en) 2014-05-13 2021-04-14 Board of Regents, The University of Texas System Gene mutations and copy number alterations of egfr, kras and met
EP3390668A4 (en) 2015-12-17 2020-04-01 Guardant Health, Inc. METHODS OF DETERMINING THE NUMBER OF TUMOR GENE COPIES BY ACELLULAR DNA ANALYSIS
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
DE69322266T2 (de) 1992-04-03 1999-06-02 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU775179B2 (en) 1999-03-15 2004-07-22 Applied Biosystems, Llc Probe/mobility modifier complexes for multiplex nucleic acid detection
EP1313880A2 (en) 2000-05-30 2003-05-28 PE Corporation (NY) Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AU2003239505A1 (en) 2002-05-20 2003-12-12 Amgen Fremont Inc. Treatment of renal carcinoma using antibodies against the egfr
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
BRPI0508286B8 (pt) 2004-03-31 2021-05-25 Dana Farber Cancer Inst Inc método para determinar a probabilidade de eficácia de um inibidor da tirosina quinase egfr para tratar câncer, uso de um inibidor da tirosina quinase de egfr, sonda, kit, e, par de iniciadores
US7932026B2 (en) * 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
CA2584723A1 (en) * 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna
BRPI0609615A2 (pt) 2005-04-01 2010-04-27 Amgen Inc métodos de predição da eficácia de tratamento de agente de ligação especìfica a egfr em tratamento de cáncer relacionado com egfr num sujeito, de tratamento do mesmo e de determinação da eficácia de tratamento em paciente
US20090269344A1 (en) * 2005-04-14 2009-10-29 Salvatore Siena Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
ES2398709T5 (es) * 2005-06-28 2017-04-18 Genentech, Inc. Mutaciones en EGFR y KRAS para predecir la respuesta de un paciente al tratamiento con inhibidores de EGFR
US8703769B2 (en) * 2005-07-15 2014-04-22 The University Of North Carolina At Chapel Hill Use of EGFR inhibitors to prevent or treat obesity
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008033442A2 (en) * 2006-09-12 2008-03-20 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for performing low background multiplex nucleic acid amplification reactions
WO2008112274A2 (en) * 2007-03-13 2008-09-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy

Also Published As

Publication number Publication date
EP2465950A3 (en) 2013-03-13
RS53265B2 (sr) 2022-06-30
SI2465950T1 (sl) 2017-11-30
SI2121989T2 (sl) 2022-05-31
EP2121989B2 (en) 2022-03-09
AR065687A1 (es) 2009-06-24
HRP20140360T4 (hr) 2022-06-10
DK2121989T3 (da) 2014-04-28
TW200902553A (en) 2009-01-16
CY1119112T1 (el) 2018-02-14
ES2635051T3 (es) 2017-10-02
AU2008226803A1 (en) 2008-09-18
RS53265B (en) 2014-08-29
US20190048423A1 (en) 2019-02-14
HRP20171509T1 (hr) 2017-11-17
RS56422B1 (sr) 2018-01-31
DK2465950T3 (en) 2017-10-09
US11155876B2 (en) 2021-10-26
PL2121989T3 (pl) 2014-07-31
LT2465950T (lt) 2017-10-10
PT2121989E (pt) 2014-04-30
EP2465950B1 (en) 2017-07-12
DK2121989T4 (da) 2022-06-20
SI2121989T1 (sl) 2014-06-30
ES2458626T3 (es) 2014-05-06
US10030270B2 (en) 2018-07-24
CY1115333T1 (el) 2017-01-04
EP2121989A2 (en) 2009-11-25
EP2465950A2 (en) 2012-06-20
US20120264129A1 (en) 2012-10-18
PE20081880A1 (es) 2008-12-31
PT2465950T (pt) 2017-10-17
CL2008000717A1 (es) 2008-09-22
MX2009009787A (es) 2009-09-22
PL2121989T5 (pl) 2023-03-06
ES2458626T5 (es) 2022-04-29
WO2008112269A2 (en) 2008-09-18
HRP20140360T1 (en) 2014-05-23
US20080293055A1 (en) 2008-11-27
PL2465950T3 (pl) 2017-12-29
CA2680326A1 (en) 2008-09-18
JP2010521153A (ja) 2010-06-24
WO2008112269A3 (en) 2008-11-20
EP2121989B1 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
US11155876B2 (en) K-ras mutations and anti-EGFr antibody therapy
EP2412828B1 (en) K-ras and B-raf mutations and anti-EGFr antibody therapy
CA2601936C (en) Epidermal growth factor receptor mutations
AU2018219977B2 (en) K-ras mutations and anti-EGFr antibody therapy field
AU2014206164A1 (en) K-ras mutations and anti-EGFr antibody therapy field
AU2013201896A1 (en) Epidermal growth factor receptor mutations